• BlossomHill flagged updated Phase 1/2 SOLARA data for BH-30643 in EGFR-mutant NSCLC with secondary resistance mutations.
• Results will be presented September 15, 2026 at the World Conference on Lung Cancer in Seoul.
• Study readout points to anti-tumor activity in patients with C797S-linked resistance across varied prior treatment histories.
• FDA Fast Track status supports development in C797S-positive resistance, a market with no approved oral targeted therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blossomhill Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010700PRIMZONEFULLFEED9819034) on September 01, 2026, and is solely responsible for the information contained therein.